Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
Right now I think all Alzheimers drugs are in favor, people just throwing money at the category now that FDA approved one drug, they think BIIB's results are relatively easy one to improve upon.

I don't see how you can talk about aducanumab setting a new standard and easing the way for other anti-Alzheimer's drugs to follow suit. The approval has been reviled by those on the evaluation panel, who (all except 1, I think) strongly called for it to be rejected. The reason? The data indicated that it has little to no benefit--basically no impact--and requires regular costly brain MRI monitoring because of the high risk of brain inflammation. Most of the advisory panel has resigned, there's been a hue and cry everywhere, and a House committee is going to hold hearings. Aducanumab is basically an incredibly expensive piece of false hope with real risk of further brain damage. I would think that this will make everyone a lot more wary about singing the praises of a new Alzheimer's drug.

What's really needed first is a far better understanding of the pathology underlying Alzheimer's. Nothing that has approached it via beta-amyloid has had any success.

=sheila
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.